← Back to Patent Explorer
US3986510A Expired / Lapsed US ⏱️ 0.0 years remaining

Bioerodible ocular device

Assignee: Alza Corp
•
Filing: 1975-08-01
•
Granted: 1976-10-19
•
Expires: 1995-08-01
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract An ocular insert for the continuous controlled administration of a predetermined therapeutically effective dosage of drug to the eye over a prolonged period of time. The device meters the flow of drug by means of a drug release rate controlling material. The insert bioerodes in the environment of the eye concurrently with the dispensing or at a point in time after the dispensing of the therapeutically desired amount of drug.

Inventors

  • 👤 Takeru Higuchi
  • 👤 Anwar A. Hussain
  • 👤 John W. Shell

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-25 10:15
CPC Classifications
A; A61; A61F; A61F9/00; A61F9/0008; A61F9/0017; A61K; A61K9/00; A61K9/0012; A61K9/0048; A61K9/0051

Claims Analysis

Total Claims: 6
Claim 1
Independent Claim 187 words
A bioerodible ocular device for the controlled continuous administration of a predetermined dosage of drug to the eye, comprising (1) an inner reservoir containing a drug formulation confined therein, and (2) an outer membrane formed from drug release rate controlling bioerodible material surrounding the inner reservoir, the membrane being permeable to passage of drug, but at a lower rate than through the inner reservoir, the device being of an initial shape which is adapted for insertion and retention in the sac of the eye bounded by the surfaces of the bulbar conjunctiva of the sclera of the eyeball and the palpebral conjunctiva of the lid, whereby release of drug from the device to the eye is effected primarily by a permeation control release mechanism in which the outer membrane continuously meters the flow of a therapeutically effective amount of drug from the reservoir to the eye at a controlled rate over a prolonged period of time, and wherein the device bioerodes in the environment of the eye concurrently with the dispensing or at a point in time after the dispensing of the therapeutically desired amount of drug.
Claim 2
Dependent Claim 187 words
A bioerodible ocular device for the controlled continuous administration of a predetermined dosage of drug to the eye, comprising (1) an inner reservoir containing a drug formulation confined therein, and (2) an outer membrane formed from drug release rate controlling bioerodible material surrounding the inner reservoir, the membrane being permeable to passage of drug, but at a lower rate than through the inner reservoir, the device being of an initial shape which is adapted for insertion and retention in the sac of the eye bounded by the surfaces of the bulbar conjunctiva of the sclera of the eyeball and the palpebral conjunctiva of the lid, whereby release of drug from the device to the eye is effected primarily by a permeation control release mechanism in which the outer membrane continuously meters the flow of a therapeutically effective amount of drug from the reservoir to the eye at a controlled rate over a prolonged period of time, and wherein the device bioerodes in the environment of the eye concurrently with the dispensing or at a point in time after the dispensing of the therapeutically desired amount of drug.
Claim 3
Dependent Claim 46 words
The ocular device defined by claim 1 wherein the outer membrane material has a release rate to drug and an erosion rate in the eye such that the drug is essentially depleted from the inner reservoir prior to the substantially complete bioerosion of the membrane material.
Claim 4
Dependent Claim 27 words
The ocular device defined by claim 1 wherein the drug permeation rate through the inner reservoir is at least twice the permeation rate through the outer membrane.
Claim 5
Dependent Claim 33 words
The ocular device defined by claim 1 wherein the inner reservoir comprises a matrix material selected from the group consisting of solid matrix materials and microporous matrix materials having the drug dispersed therethrough.
Claim 6
Dependent Claim 21 words
The ocular device defined by claim 1 wherein the inner reservoir comprises a hollow container having the drug formulation confined therein.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1979-10-19 1980-04-19 1980-10-19 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1983-10-19 1984-04-19 1984-10-19 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1987-10-19 1988-04-19 1988-10-19 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag